Log in to search using one of your social media accounts:

 

Omalizumab Response Varies by Asthma Type Omalizumab Response Varies by Asthma Type
Patients with specific phenotypes of severe asthma derive greater benefit from the biologic treatment than others, a multicenter, retrospective study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Omalizumab Protects Against Early, Late Allergic Responses
Significant reduction in early allergic reaction after 4 weeks, with decrease in FEV1, exhaled nitric oxide (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 9, 2017 Category: Respiratory Medicine Tags: Pharmacy, Pulmonology, Allergy, Journal, Source Type: news

Anti-IgE Drug Might Change Asthma Course (CME/CE)
(MedPage Today) -- Lung improvement observed in children treated with omalizumab (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - May 24, 2017 Category: Allergy & Immunology Source Type: news

omalizumab, Xolair
Title: omalizumab, XolairCategory: MedicationsCreated: 5/27/2004 12:00:00 AMLast Editorial Review: 5/15/2017 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - May 15, 2017 Category: Respiratory Medicine Source Type: news

FDA okays Glenmark's first-in-human study for respiratory drug
According to IMS sales data for the 12-month period ending February 2017, annual sales of XOLAIR 150 mg injection was approximately $1.7 billion in the US. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 25, 2017 Category: Pharmaceuticals Source Type: news

Xolair Tx Tied to Less Hospital Time in Young Asthmatic Kids
(MedPage Today) -- Omalizumab cut incidence of unscheduled healthcare visits for ages 6-12 years (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - November 13, 2016 Category: Allergy & Immunology Source Type: news

Omalizumab Offers Improvements in Patients with Asthma-COPD (CME/CE)
(MedPage Today) -- Better asthma control and QoL scores, but no lung function improvement (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - November 8, 2016 Category: Allergy & Immunology Source Type: news

Xolair Offers Improvements in Patients with Asthma-COPD (CME/CE)
(MedPage Today) -- Better asthma control and QoL scores, but no lung function improvement (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 8, 2016 Category: Primary Care Source Type: news

Drop-Out Rate in Omalizumab Treatment for Severe Asthma Drop-Out Rate in Omalizumab Treatment for Severe Asthma
Find out more about the omalizumab drop-out rate among patients with severe asthma. What are the common reasons for poor treatment adherence?BMC Pulmonary Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 6, 2016 Category: Allergy & Immunology Tags: Pulmonary Medicine Journal Article Source Type: news

Xolair (Omalizumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 18, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Expands Xolair to Younger Kids With Allergic AsthmaFDA Expands Xolair to Younger Kids With Allergic Asthma
Omalizumab is now indicated in children as young as age 6 years with uncontrolled moderate to severe persistent allergic asthma. FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 11, 2016 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Alert Source Type: news

Genentech's Xolair receives US FDA approval for allergic asthma treatment
Roche Group member Genentech has received the Food and Drug Administration (FDA) approval for Xolair (omalizumab) to treat children with moderate to severe persistent allergic asthma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 10, 2016 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Xolair (omalizumab) for Allergic Asthma in Children
South San Francisco, CA -- July 7, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) to treat moderate to severe persistent... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 7, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
South San Francisco, CA -- July 7, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) to treat moderate to severe persistent... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 7, 2016 Category: Drugs & Pharmacology Source Type: news

Omalizumab cost effective for chronic urticaria in UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 31, 2016 Category: Drugs & Pharmacology Source Type: news

Roche reports solid sales growth in the first quarter of 2016
In the first quarter of 2016, Group sales rose 4% to CHF 12.4 billion. Sales in the Pharmaceuticals Division were up 4% to CHF 9.8 billion with Europe growing 5%, driven by Perjeta, MabThera and RoActemra. Pharmaceuticals sales in the US increased 3%, led by Esbriet, Xolair and HER2-positive breast cancer medicines. The recently launched medicines Cotellic in skin cancer and Alecensa in lung cancer have had a good start. (Source: World Pharma News)
Source: World Pharma News - April 19, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Omalizumab improves quality of life, angioedema in refractory urticaria patients
WASHINGTON – Treatment with omalizumab improved quality-of-life scores and had a significant impact on angioedema episodes in a phase IIIb study of people with treatment-refractory chronic idiopathic/spontaneous urticaria. In the double-blind
Source: Skin and Allergy News - March 15, 2016 Category: Dermatology Source Type: news

Omalizumab decreases colds in inner-city children with asthma
Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers report. Omalizumab, sold under the brand name Xolair, is an injectable antibody that can be used to treat asthma cases not controlled by inhaled corticosteroids. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 7, 2016 Category: Science Source Type: news

Xolair May Reduce Rate of Cold Symptoms in Asthmatic Kids
(MedPage Today) -- Study assessed omalizumab paired with guideline-based treatment (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 7, 2016 Category: Allergy & Immunology Source Type: news

Omalizumab decreases colds in inner-city children with asthma, NIH study reports
(NIH/National Institute of Allergy and Infectious Diseases) Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers reported at a press conference today at the American Academy of Allergy, Asthma and Immunology 2016 Annual Meeting in Los Angeles. Omalizumab, sold under the brand name Xolair, is an injectable antibody that can be used to treat asthma cases not controlled by inhaled corticosteroids. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 5, 2016 Category: Global & Universal Source Type: news

Better targeting of treatment gives hope to people with severe asthma
(NIHR Office for Clinical Research Infrastructure) A new study brings hope to severe allergic asthma patients by investigating whether the drug Omalizumab can be better targeted. The antibody treatment Omalizumab is an approved therapy for people who do not respond to steroid treatment and it is hoped that better targeting could save both lives and money in the NHS. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 1, 2016 Category: Global & Universal Source Type: news

JACI Publishes Results from Oral Immunotherapy Study with Omalizumab
First Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab in Patients with Severe Milk Allergy(PRWeb November 12, 2015)Read the full story at http://www.prweb.com/releases/2015/11/prweb13079239.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 13, 2015 Category: Pharmaceuticals Source Type: news

Published in JACI: New Asthma Treatment Strategy With Omalizumab...
Researchers’ introduce biologic treatments for asthmatics prone to exacerbations(PRWeb October 27, 2015)Read the full story at http://www.prweb.com/releases/2015/10/prweb13046602.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 27, 2015 Category: Pharmaceuticals Source Type: news

Your NEJM Group Today: Acute Colonic Pseudo-Obstruction Image, Omalizumab for Chronic Hives, Mass. Primary Care Opportunity (FREE)
By The Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 29, 2015 Category: Primary Care Source Type: news

Chronic Idiopathic Urticaria: Treatment With OmalizumabChronic Idiopathic Urticaria: Treatment With Omalizumab
Learn more about omalizumab, a fully humanized monoclonal antibody which shows promise as a new third-line option for chronic spontaneous urticaria, a common autoimmune skin condition. Skin Therapy Letter (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 27, 2015 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

Pennsylvania Xarelto Lawsuits Consolidated With Creation of Mass Tort...
The Firm is representing plaintiffs in Xarelto lawsuits that allege the blood thinner places patients at risk for uncontrollable internal bleeding and other life-threatening complications.(PRWeb January 23, 2015)Read the full story at http://www.prweb.com/releases/xarelto-lawsuit/xolair-side-effects/prweb12467948.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 24, 2015 Category: Pharmaceuticals Source Type: news

Xarelto Lawsuit Alleges Illinois Woman Suffered Life-Threatening...
The Firm is representing plaintiffs in Xarelto lawsuits who allegedly suffered uncontrollable internal bleeding and other complications related to its use.(PRWeb November 21, 2014)Read the full story at http://www.prweb.com/releases/xolair-lawsuit/xarelto-bleeding/prweb12346384.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 22, 2014 Category: Pharmaceuticals Source Type: news

Roche delivers solid sales growth for the first nine months of 2014
Group sales up 5% at CER, stable in Swiss francs; 4% higher sales in Pharmaceuticals Division, with strong growth of oncology portfolio, as well as Actemra for rheumatoid arthritis and Xolair for asthma and chronic hives; 6% higher sales in Diagnostics Division, driven by strong Professional Diagnostics’ performance (Source: Roche Investor Update)
Source: Roche Investor Update - October 16, 2014 Category: Pharmaceuticals Source Type: news

Roche delivers solid sales growth for the first nine months of 2014
Group sales up 5% at CER, stable in Swiss francs; 4% higher sales in Pharmaceuticals Division, with strong growth of oncology portfolio, as well as Actemra for rheumatoid arthritis and Xolair for asthma and chronic hives; 6% higher sales in Diagnostics Division, driven by strong Professional Diagnostics’ performance (Source: Roche Media News)
Source: Roche Media News - October 16, 2014 Category: Pharmaceuticals Source Type: news

Xolair Side Effect Claims Being Evaluated by Bernstein Liebhard LLP on...
The Firm is evaluating legal claims on behalf of individuals who allegedly suffered serious Xolair side effects, including heart attacks, mini-strokes, pulmonary hypertension, and blood clots in the...(PRWeb October 01, 2014)Read the full story at http://www.prweb.com/releases/xolair-lawsuit/xolair-side-effects/prweb12216415.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 2, 2014 Category: Pharmaceuticals Source Type: news

FDA Warns on Xolair's (omalizumab) Serious Adverse Events:...
On September 26, the FDA issued a safety communication on potential risks of cardiovascular and cerebrovascular serious adverse events to Xolair's (omalizumab) drug label. In light of this news,...(PRWeb September 30, 2014)Read the full story at http://www.prweb.com/releases/2014/10/prweb12208816.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 30, 2014 Category: Pharmaceuticals Source Type: news

Small Heart, Stroke Risks From Asthma Drug: FDA
A safety study done by the maker of the asthma drug omalizumab (Xolair) suggests it poses slightly increased but serious risks for heart attacks and mini-strokes known as TIAs (transient ischemic attacks), the FDA says. (Source: WebMD Health)
Source: WebMD Health - September 29, 2014 Category: Consumer Health News Source Type: news

Cardiovascular and Cerebrovascular Warnings Added to Omalizumab's Label (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH The FDA has updated the label for the asthma drug omalizumab (Xolair) with new warnings about the elevated risk for cardiovascular and cerebrovascular … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 29, 2014 Category: Primary Care Source Type: news

FDA says asthma drug Xolair raises risk of heart, brain problems
WASHINGTON (Reuters) - The asthma drug Xolair is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems, though the extent of increased risk is unclear, the U.S. Food and Drug Administration said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - September 26, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Warns of Small Cardio, Cerebrovascular Risk With XolairFDA Warns of Small Cardio, Cerebrovascular Risk With Xolair
The agency hedged its warning by saying the findings come from a manufacturer's safety study with 'weaknesses.' News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 26, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

Xolair (omalizumab): Drug Safety Communication - Slightly Elevated Risk of Cardiovascular and Cerebrovascular Serious Adverse Events
FDA approves label changes after review of a five year safety study. (Source: FDA MedWatch)
Source: FDA MedWatch - September 26, 2014 Category: American Health Source Type: news

Omalizumab Effective for Chronic Hives up to 24 WeeksOmalizumab Effective for Chronic Hives up to 24 Weeks
The 300-mg dose of omalizumab was most effective compared with placebo, but symptoms recur after treatment is discontinued. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 28, 2014 Category: Consumer Health News Tags: Dermatology News Source Type: news

Asthma Drug May Help Those With Chronic Hives
Xolair found safe, effective for reducing symptoms, study finds (Source: WebMD Health)
Source: WebMD Health - July 21, 2014 Category: Consumer Health News Source Type: news

Asthma Drug May Help Those with Chronic Hives
Xolair found safe, effective for reducing symptoms, study finds Source: HealthDay Related MedlinePlus Pages: Hives, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 21, 2014 Category: Consumer Health News Source Type: news

Xolair (Omalizumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 10, 2014 Category: Drugs & Pharmacology Source Type: news

FDA approves Xolair® (omalizumab) for people with Chronic Idiopathic Urticaria (CIU), a form of chronic hives
Novartis has announced that the US Food and Drug Administration (FDA) approved Xolair® (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (hives) and is not for use in children less than 12 years of age. Xolair is jointly developed by Genentech and Novartis Pharma AG and is co-promoted by Novartis Pharmaceuticals Corporation with Genentech in the United States. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2014 Category: Consumer Health News Tags: Dermatology Source Type: news

FDA approves Xolair (omalizumab) for people with Chronic Idiopathic Urticaria, a form of chronic hives
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Until now, H1-antihistamines have been the only approved therapy for CIU, with about 50 percent of patients having an inadequate response. (Source: Roche Investor Update)
Source: Roche Investor Update - March 24, 2014 Category: Pharmaceuticals Source Type: news

FDA approves Xolair (omalizumab) for people with Chronic Idiopathic Urticaria, a form of chronic hives
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Until now, H1-antihistamines have been the only approved therapy for CIU, with about 50 percent of patients having an inadequate response. (Source: Roche Media News)
Source: Roche Media News - March 24, 2014 Category: Pharmaceuticals Source Type: news

FDA OKs Omalizumab (Xolair) for Chronic HivesFDA OKs Omalizumab (Xolair) for Chronic Hives
Omalizumab is indicated for people aged 12 years or older with chronic idiopathic urticaria who fail to find relief with antihistamines. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Alert Source Type: news

FDA Approves Xolair for Chronic Hives
(MedPage Today) -- The FDA has approved omalizumab (Xolair) for treatment of chronic idiopathic urticaria, drugmaker Genentech announced. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 21, 2014 Category: Primary Care Source Type: news

Omalizumab Appears to Improve Oral ImmunotherapyOmalizumab Appears to Improve Oral Immunotherapy
Omalizumab can increase the benefits of oral immunotherapy for milk allergy and reduce the adverse effects, a new study suggests. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

New indication for Xolair approved by the European Commission for treatment in chronic spontaneous urticaria patients
Novartis has announced that the European Commission (EC) has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients, who do not respond to the current mainstay of therapy, H1 antihistamines. The approved dose in CSU is 300 mg administered by subcutaneous injection once every four weeks. Prescribers are advised to periodically reassess the need for continued therapy. Clinical trial experience of treatment beyond six months in this indication is limited. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 10, 2014 Category: Consumer Health News Tags: Dermatology Source Type: news

Novartis' Urticaria drug Xolair obtains EU approval
Novartis has received approval from the European Commission (EC) to use Xolair (omalizumab) as an add-on therapy to treat chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response to H1-antihista… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 10, 2014 Category: Pharmaceuticals Source Type: news

Xolair Makes Milk Allergy Tx More Tolerable
SAN DIEGO (MedPage Today) -- Giving omalizumab (Xolair) around the start of oral immunotherapy for milk allergy improved safety, a randomized trial confirmed. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 5, 2014 Category: Pediatrics Source Type: news

Asthma Drug Helps Desensitize Multiple Food Allergies Faster in Early Studies (FREE)
By Kelly Young An early trial suggests that the monoclonal antibody omalizumab can speed up oral immunotherapy in patients with multiple food allergies. Results of the phase 1 safety trial were published in Allergy, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 3, 2014 Category: Primary Care Source Type: news